Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $46.0909.

Several research analysts have weighed in on CAPR shares. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Wall Street Zen lowered shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. B. Riley Financial upped their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th.

Insider Buying and Selling at Capricor Therapeutics

In other news, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CAPR. Suvretta Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $51,533,000. Tang Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $43,516,000. Darwin Global Management Ltd. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $23,168,000. Finally, SB Capital Management Inc acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $11,544,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $30.38 on Friday. The firm has a market cap of $1.76 billion, a PE ratio of -13.44 and a beta of 0.48. The firm’s 50 day moving average price is $31.45 and its two-hundred day moving average price is $23.34. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Equities analysts anticipate that Capricor Therapeutics will post 0.01 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.